Clinical trials: Residual
Leukemia, Myelodysplastic Syndromes
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
This is a Phase I, multicenter, open-label, non-randomized study of matched unrelated donor BPX-501 T cell infusion in adult subjects with hematological malignancies presenting with recurrent disease minimal residual disease…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphomas, Multiple Myeloma
- Trial name
- NCT02786485
- Testing
- rivogenlecleucel, Rimiducid
- Sponsor
- Bellicum Pharmaceuticals
Amputation
Amputee Residual Limb Volume Fluctuation
The goal of this project is a useful clinical instrument for diagnosis and treatment of residual limb volume fluctuation in individuals who use prosthetic limbs.
- Trial name
- NCT01161238
- Testing
- Monitored for limb volume
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Washington
ST-elevation Myocardial Infarction
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients with high on ticagrelor platelet…
- Trial name
- ERMIT (NCT04927949)
- Testing
- cangrelor perfusion during PCI, standard PCI
- Where
- France
- Volunteers
- 128 people
- Sponsor
- University Hospital, Caen
Bipolar Disorder
Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients
The goals of this study are to evaluate the efficacy of JNJ-18038683 in an 8 week trial to ameliorate the cognitive deficit and reduce residual depressive symptoms in 60 stable bipolar outpatients receiving treatment for…
- Trial name
- NCT02466685
- Testing
- JNJ-18038683
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Herbert Meltzer
Gastric Residual Volume, Aspiration Risk
Gastric Residual Volume and Aspiration Risk Following Intravenous Metoclopramide in Fasted Diabetic Patients Undergoing Elective Surgery
This study aimed to evaluate the effect of metoclopramide on preoperative gastric emptying in diabetic patients.
- Conditions
- Gastric Residual Volume, Aspiration Risk, Metoclopramide, Fasted Diabetic Patients
- Trial name
- NCT07519447
- Testing
- Metoclopramide
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kafrelsheikh University
Colon Cancer, Resected Stage
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for…
- Trial name
- NCT05040568
- Testing
- Cetuximab, Expanded CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid, Acute
Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)
This retrospective multicentre cohort evaluates the agreement of measurable residual disease (MRD) detection in acute myeloid leukaemia (AML) using two flow-cytometry gating approaches.
- Trial name
- DUALFLOW (NCT07269067)
- Testing
- Conventional gating, Automated gating
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Gastric Content Aspiration Risk, Gastrointestinal Endoscopy
BBCMADE Nomogram Validation for High-Risk Gastric Content in Sedative Endoscopy
This prospective observational study aims to validate the BBCMADE nomogram (Body Mass Index, Brain infarction, Cirrhosis, Male sex, Age, Diabetes, Esophageal reflux) for predicting high-risk gastric content in patients undergoing…
- Conditions
- Gastric Content Aspiration Risk, Gastrointestinal Endoscopy, Anesthesia Complications
- Trial name
- BBCMADE (NCT07638917)
- Testing
- BBCMADE Nomogram, Endoscopic Gastric Volume and pH Measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 533 people
- Sponsor
- Fusun Gozen
Type 1 Diabetes
The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D)
The primary aim of this pilot study is to test whether gluten-free diet (GFD) instituted in children shortly after onset of Type 1 Diabetes (T1D) can decelerate the decline in beta cell function as compared to age matched…
- Trial name
- NCT02867436
- Testing
- Gluten-free diet
- Where
- 2 sites in Czechia
- Volunteers
- 45 people
- Sponsor
- University Hospital, Motol
Overactive Bladder
In-office Assessment of Voiding Function Following Botox Injection for Overactive Bladder
The purpose of this study is to describe the rates of elevated post void residual (PVR) (defined as >200mL) in Cincinnati Urogynecology Associates patients following Botox injection, as well as to document how many patients…
- Trial name
- NCT04155593
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- TriHealth Inc.
MRD, Prostate Cancer
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
- Conditions
- MRD, Prostate Cancer, mHSPC
- Trial name
- NCT07112612
- Volunteers
- 50 people
- Sponsor
- Anhui Medical University
Pancreatic Cancer, Resectable Carcinoma
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer.
- Trial name
- MAP-02 (NCT05802407)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Breast, Metastatic
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
This study looks to advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure…
- Conditions
- Breast, Metastatic, Triple Negative, Cancer
- Trial name
- EMPOWER (NCT04333706)
- Testing
- Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of Southern California
Head and Neck Cancer
Exploratory Study of Clonal Evolution in Cancer for Patients Undergoing Transoral Robotic Surgery for Radiation Exposed Residual/reCurrent Tumours of the Upper Aerodigestive Tract
Radical radiotherapy for head and neck squamous cell cancer (HNSCC) can be administered to primary disease with curative intent. Residual disease, recurrence or further tumours may subsequently occur in this irradiated field.
- Trial name
- RECUT Plus (NCT04671940)
- Testing
- DNA Analysis
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Diabetes Mellitus, Type 1
DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen
The objectives of this study is to evaluate the safety and influence of treatment with GAD-Alum (Diamyd) combined with Vitamin D and Ibuprofen on preservation of residual insulin secretion in recently diagnosed Type 1 Diabetes…
- Trial name
- NCT01785108
- Testing
- GAD-Alum (Diamyd) 20 µg, GAD-Alum (Diamyd) 20 µg X 2, Vitamin D
- Where
- 10 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Johnny Ludvigsson
Fitting Methods by EAS Patients
Optimization and Validation of Electric Acoustic Stimulation (EAS) Mapping as a Function of Residual Hearing After CI-Implantation
The aim of this clinical study is to investigate how the fitting of an EAS (electrical acoustic stimulation) based on electrocochleography (ECochG) thresholds compares to fitting based on pure tone audiogram thresholds in terms…
- Trial name
- NCT07476079
- Testing
- The objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study., The subjective adjustment of an EAS based on thresholds from the pure tone audiogram.
- Volunteers
- 12 people
- Sponsor
- Luzerner Kantonsspital
Multiple Myeloma
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy…
- Trial name
- NCT04140162
- Testing
- Daratumumab, Lenalidomide, Bortezomib
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- University of Michigan Rogel Cancer Center
End-Stage Renal Disease, Type 2 Diabetes Mellitus
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis
This study is a multi-center, double-blinded, randomized, study of bardoxolone methyl treatment in patients with End-Stage Renal Disease (ERSD) and Type 2 Diabetes Mellitus (T2DM) on peritoneal dialysis.
- Trial name
- NCT01576887
- Testing
- Bardoxolone Methyl 20 mg
- Sponsor
- Biogen
Breast Neoplasm, Triple Negative Breast Cancer (TNBC)
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patient allocation via minimisation (cohorts A-D) or allocation according to HRD and…
- Conditions
- Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD
- Trial name
- PHOENIX (NCT03740893)
- Testing
- AZD6738, Olaparib, Durvalumab
- Where
- 6 sites in United Kingdom
- Volunteers
- 119 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer, HER2-positive Breast Cancer
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
This is a Phase 2 study for patients with resected Stage I-III HER2+ breast cancer with detected molecular residual disease (MRD+) following standard neoadjuvant and locoregional therapy delivered with curative intent.
- Trial name
- NCT05388149
- Testing
- Neratinib
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.